Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma
- 1 September 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 22 (9) , 1021-1027
- https://doi.org/10.1097/00006231-200109000-00012
Abstract
The aims of this study were to evaluate the efficacy of an empirically determined ‘fixed’ high ablative dose of radioiodine (131I) therapy and to determine the utility of ultrasonography (US) in dose determination. A retrospective analysis was performed of 242 thyroid cancer cases treated with ‘fixed’ high-dose 131I for ablation of thyroid remnants without a pre-ablative 131I diagnostic scintigraphy or radioiodine uptake study. Treatment doses ranged from 1850 MBq (50 mCi) to 7.4 GBq (200 mCi). The selection of the treatment dose was based on the surgical and pathological findings as well as the remnant thyroid volume calculated by US. A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Successful ablation was obtained in 218 of the 242 patients (90%). In 162 of the 218 patients (74.3%), successful ablation was achieved after a single 131I treatment. The remnant thyroid volume calculated by US was significantly different (P = 0.04) between those who were successfully ablated and those who were not. The total 131I dose needed for successful ablation was significantly higher in males (P = 0.003). Patients with higher post-operative thyroglobulin (Tgb) levels and patients with a higher stage of disease required higher doses (P = 0.036 and P = 0.021 respectively). Serum Tgb levels were under 10 ng·ml−1 in 220 of the 242 patients (90%) following radioiodine ablation while not receiving L-thyroxine suppression. Nineteen patients (7.8%) showed metastases on post-therapy scan and successful treatment was achieved in 11 of 19 (57.8%). Four of the 19 patients with distant metastases (revealed on post-treatment scan) were found to have been given a treatment dose of less than 200 mCi based on the proposed empirical approach. These results indicate that ‘fixed’ high-dose 131I treatment is clinically feasible with an acceptable dose underestimation rate, and the utilization of US in the determination of the thyroid remnant volume provides more accurate and reproducible results.Keywords
This publication has 30 references indexed in Scilit:
- Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphyNuclear Medicine Communications, 2000
- Use of Thyroid Ultrasound Volume in Calculating Radioactive Iodine Dose in HyperthyroidismThyroid®, 2000
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Thyroid Remnant 131I Ablation for Papillary and Follicular Thyroid CarcinomaThyroid®, 1997
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994
- Influence of Diagnostic Radioiodines on the Uptake of Ablative Dose of Iodine-131Thyroid®, 1994
- Fractionated Doses of Radioiodine for Ablation of Postsurgical Thyroid Tissue RemnantsClinical Nuclear Medicine, 1990
- High or low dose radioiodine ablation of thyroid remnants?European Journal of Nuclear Medicine and Molecular Imaging, 1987
- Radionuclide diagnosis and therapy of thyroid cancer: Current status reportSeminars in Nuclear Medicine, 1985
- PAPILLARY THYROID CARCINOMAMedicine, 1977